bioAffinity Partners with Pictor to Develop Precision Diagnostics for Asthma and COPD
Event summary
- bioAffinity Technologies partners with Pictor to develop and commercialize next-generation diagnostics for asthma and COPD, leveraging flow cytometry and targeted proteomic analysis.
- The collaboration aims to provide physicians with a more complete understanding of lung inflammation in real time, supporting precision medicine approaches.
- bioAffinity will own the intellectual property associated with the tests, while Pictor retains its existing IP related to its proteomic platform technology.
- The global asthma and COPD therapeutics market is projected to exceed $155 billion by 2030, driven by increasing use of targeted therapies and biologics.
The big picture
This partnership aligns with the broader trend towards precision medicine in respiratory diseases, where understanding individual inflammatory pathways is key to effective treatment. The collaboration leverages bioAffinity's expertise in immune cell biology and Pictor's scalable proteomic platform to address a market projected to exceed $155 billion by 2030. The success of this initiative could set a precedent for similar diagnostic developments in other chronic respiratory conditions.
What we're watching
- Market Expansion
- Whether bioAffinity can successfully scale its diagnostics to capture a significant share of the growing asthma and COPD market.
- Regulatory Headwinds
- The pace at which evolving regulations for laboratory-developed tests may impact commercialization timelines.
- Execution Risk
- How bioAffinity and Pictor will manage the integration of their technologies to ensure high-throughput testing efficiency.
Related topics